Evidence map›Paper›PMID 40208380›Full record

ReviewCurrent urology reports2025

Management of Patients with Muscle-Invasive Bladder Cancer Achieving A Clinical Complete Response after Neoadjuvant Therapy: Evidence and Consideration for Active Surveillance.

Benjamin I Joffe, John R Christin, Clémentine Le Coz, Srinath-Reddi Pingle, Alexander Z Wei, Karie D Runcie, Mark N Stein, Guarionex Joel DeCastro, Christopher B Anderson, James M McKiernan and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current urology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Benjamin I JoffeDepartment of Urology, Columbia University Vagelos College of Physicians and Surgeons, 161 Fort Washington Avenue, 11th Floor Herbert Irving Pavilion, New York, NY, 10032, USA.
John R ChristinDivision of Hematology/Oncology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA.
Clémentine Le CozDepartment of Biological Sciences, Graduate School of Arts and Science, Columbia University, New York, NY, 10027, USA.
Srinath-Reddi PingleDepartment of Urology, Columbia University Vagelos College of Physicians and Surgeons, 161 Fort Washington Avenue, 11th Floor Herbert Irving Pavilion, New York, NY, 10032, USA.
Alexander Z WeiDivision of Hematology/Oncology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA.
Karie D RuncieDivision of Hematology/Oncology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA.
Mark N SteinDivision of Hematology/Oncology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA.
Guarionex Joel DeCastroDepartment of Urology, Columbia University Vagelos College of Physicians and Surgeons, 161 Fort Washington Avenue, 11th Floor Herbert Irving Pavilion, New York, NY, 10032, USA.
Christopher B AndersonDepartment of Urology, Columbia University Vagelos College of Physicians and Surgeons, 161 Fort Washington Avenue, 11th Floor Herbert Irving Pavilion, New York, NY, 10032, USA.
James M McKiernanDepartment of Urology, Columbia University Vagelos College of Physicians and Surgeons, 161 Fort Washington Avenue, 11th Floor Herbert Irving Pavilion, New York, NY, 10032, USA.
Andrew T LenisDepartment of Urology, Columbia University Vagelos College of Physicians and Surgeons, 161 Fort Washington Avenue, 11th Floor Herbert Irving Pavilion, New York, NY, 10032, USA. atl2137@cumc.columbia.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo review the landscape of bladder preservation management and active surveillance for those who achieve clinical complete response to neoadjuvant chemotherapy. RECENT

findingsMultiple cohorts of patients with clinical complete response report overall survival rates over 80% multiple years after treatment without cystectomy. Most recently, prospective clinical trials have been pursuing clinical complete response as a valid primary endpoint. Recent advances in immunotherapy and molecular biomarkers present new horizons in expanding the potential patient population as well as accuracy in prediction of pathologic complete response. While neoadjuvant chemotherapy followed by radical cystectomy is the standard of care for muscle-invasive bladder cancer, interest in active surveillance is growing as evidenced by the increasing number of studies. Accumulating evidence and new prospective data suggest this could be a plausible option in the future. These cohorts remain highly selected, thus generalizability is still under investigation.

Indexed as

Neoadjuvant TherapyUrinary Bladder NeoplasmsWatchful WaitingCystectomyHumansNeoplasm InvasivenessTreatment OutcomeActive surveillanceBladder cancerClinical complete responseMuscle-invasiveNeoadjuvant

Identifiers

PMID40208380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.